World's Best Scientists 2026 revealed!
Victor M. Rivera

Victor M. Rivera

D-Index & Metrics

Biology and Biochemistry

D-Index
66
Citations
18622
World Ranking
8546
National Ranking
574

Overview

Victor M. Rivera is affiliated with Takeda in Japan and has contributed extensively to the field of medicine, with a focus on pulmonary and respiratory medicine, oncology, molecular biology, surgery, and pathology and forensic medicine. Their work primarily addresses cancer research, especially within lung and gastric cancer subfields, alongside investigations into signaling pathways relevant to cancer biology.

Their research output includes numerous papers published in notable journals, covering topics that range from lung cancer mutations to cancer mechanisms and therapies. Key recent publications include:

  • Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer, 2021, Cancer Discovery
  • Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib, 2021, Cancer Research
  • Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL, 2020, Blood Cancer Journal
  • Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer, 2022, Bioorganic & Medicinal Chemistry Letters
  • Hemorrhage Sites and Mitigation Strategies After Pancreaticoduodenectomy, 2024, JAMA Surgery

Victor M. Rivera has frequently collaborated with multiple co-authors, notably Wei-Sheng Huang, Narayana I. Narasimhan, William C. Shakespeare, Sara Nadworny, and David C. Dalgarno. These collaborations have supported their research in various aspects of oncology and molecular biology.

The main publication venues where Rivera's work appears include:

  • Cancer Research
  • Cancer Discovery
  • Blood Cancer Journal
  • Bioorganic & Medicinal Chemistry Letters
  • JAMA Surgery

Their scientific inquiries target several specific topics:

  • Lung Cancer Treatments and Mutations
  • Gastric Cancer Management and Outcomes
  • PI3K/AKT/mTOR signaling in cancer
  • Pancreatic and Hepatic Oncology Research
  • Cancer Mechanisms and Therapy
  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research

Victor M. Rivera's research spans a multidisciplinary approach within medicine, emphasizing translational cancer research and precision oncology to better understand and address complex cancer mutations and treatment pathways.

Best Publications

  • AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

    Thomas O'Hare;Thomas O'Hare;William C. Shakespeare;Xiaotian Zhu;Christopher A. Eide;Christopher A. Eide

  • A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre

  • Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

    Jorge E Cortes;Hagop M Kantarjian;Neil P. Shah;Dale Bixby

  • A HUMANIZED SYSTEM FOR PHARMACOLOGIC CONTROL OF GENE EXPRESSION

    Victor M. Rivera;Tim Clackson;Sridaran Natesan;Roy Pollock

  • Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

    Katayama R;Khan Tm;Benes C;Lifshits E

  • Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

    Jorge E. Cortes;Dong Wook Kim;Javier Pinilla-Ibarz;Philipp D. le Coutre

  • Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.

    Wei-Sheng Huang;Chester A Metcalf;Raji Sundaramoorthi;Yihan Wang

  • Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum

    Victor M. Rivera;Xiurong Wang;Scott Wardwell;Nancy L. Courage

  • Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.

    Wei-Sheng Huang;Shuangying Liu;Dong Zou;Mathew Thomas

  • Regulated Delivery of Therapeutic Proteins After in Vivo Somatic Cell Gene Transfer

    Xuehai Ye;Victor M. Rivera;Philip Zoltick;Franklin Cerasoli

  • Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.

    Monica M. Mita;Alain C. Mita;Quincy S. Chu;Eric K. Rowinsky

  • The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.

    Sen Zhang;Rana Anjum;Rachel Squillace;Sara Nadworny

  • Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

    Scott N Gettinger;Lyudmila A Bazhenova;Corey J Langer;Ravi Salgia

  • A growth factor-induced kinase phosphorylates the serum response factor at a site that regulates its DNA-binding activity.

    Victor M. Rivera;Cindy K. Miranti;Ravi P. Misra;David D. Ginty

  • Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

    Joseph M Gozgit;Matthew J Wong;Lauren Moran;Scott Wardwell

  • Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer

    Victor M. Rivera;Guang-ping Gao;Rebecca L. Grant;Michael A. Schnell

  • Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

    Tianjun Zhou;Lois Commodore;Wei-Sheng Huang;Yihan Wang

  • Long-term regulated expression of growth hormone in mice after intramuscular gene transfer

    Victor M. Rivera;Xuehai Ye;Nancy L. Courage;Jeff Sachar

  • A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

    David A. Rizzieri;Eric Feldman;John F. DiPersio;Nashat Gabrail

  • Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas

    Sant P. Chawla;Arthur P. Staddon;Laurence H. Baker;Scott M. Schuetze

Frequent Co-Authors

Tim Clackson
Tim Clackson Theseus Pharmaceuticals
Michael W. Deininger
Michael W. Deininger University of Utah
Jorge E. Cortes
Jorge E. Cortes Augusta University
Moshe Talpaz
Moshe Talpaz University of Michigan–Ann Arbor
Neil P. Shah
Neil P. Shah University of California, San Francisco
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Timothy P. Hughes
Timothy P. Hughes South Australian Health and Medical Research Institute
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Michele Baccarani
Michele Baccarani University of Bologna
Francois Guilhot
Francois Guilhot Grenoble Alpes University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

A background in Biology and Biochemistry can open doors to a variety of high-impact careers in healthcare and life sciences. If you’re looking to build on your science foundation or pursue leadership roles, there are several online degree options that could help you reach your goals.

For those interested in the business and management side of healthcare, consider exploring cahme-accredited online mha programs that prepare graduates for administrative roles in hospitals, research organizations, and biotech firms. Another strong route for scientists interested in patient care and advanced practice is a doctor of nursing practice, which allows you to impact healthcare outcomes at a systems level.

If research, policymaking, or academia is your target, a phd in healthcare administration online can equip you with the analytical and leadership skills needed for top positions. Alternatively, those focused on pharmaceuticals and drug development should consider the pharmd online programs to qualify for advanced clinical and industry roles.

Each of these specialized online degrees can build upon your biology background, helping you carve out a rewarding and flexible career across the health and bioscience spectrum.

Best Scientists Citing Victor M. Rivera

Trending Scientists

Recently Published Articles